- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Prostate Cancer Study Proves Drug Delays Disease Progression
For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride (“Avodart”) delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a 3-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).
The findings are published online today in The Lancet. “The results prove that using active surveillance plus dutasteride is a viable, safe and effective treatment option for men who often undergo aggressive local treatment despite low risk of dying from the disease,” says Dr. Fleshner, a surgical oncologist in UHN’s Princess Margaret Cancer Program and Professor of Surgery at the University of Toronto. Dr. Fleshner also holds the Love Chair in Prostate Cancer Prevention Research.
“This is very good news for men with low-risk disease because aggressive treatment can have a major impact on their quality of life, with risks of impotence and incontinence,” says Dr. Fleshner.
Read more at: http://www.newswise.com/articles/view/584901/?sc=dwhr&xy=10006693
Source: Newswise
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
